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used. In contrast, when donor PBMCs (without artiﬁcial
APCs) were used as the source of APCs, 10-100 fold fewer
Tregs were obtained. Regardless of protocol, pTregs suc-
cessfully prevented the proliferation of bead (CD2CD3CD28)
stimulated self PBMCs with up to 50% suppression at a 1:32
ratio of Tregs:PBMCs.
Contamination of CD8+ T cells was observed despite our ef-
forts to gate out CD8 cells during sorting. Re-sorting of the
Treg cultures early (day 14-21 post isolation) successfully
eliminated the CD8s. Re-sorting inherently caused a signiﬁ-
cant loss of Tregs, leading to a longer culture period. Because
Treg burnout was of concern, we assessed the function and
phenotype of cells maintained in cultures >50 days and
observed that Tregs with early high FoxP3 expression
maintained function and phenotype.
Finally, demonstration of ﬁtness of cryopreserved pTregs is
necessary for clinical application. Our preliminary studies
show that Tregs can be re-cultured and re-expanded without
loss of suppression or phenotype. In summary, we have
successfully established several protocols for Treg expansion
in the Cynomolgus macaque that can be used in pre-clinical
studies of transplant tolerance induction.400
High Rates of Early Donor Chimerism in Intermediate and
Poor Risk Patients Undergoing Stem Cell Transplantation
Using Reduced Toxicity Ablative Conditioning Regimen
Incorporating Busulfan Pharmacokinetics
Shatha Farhan 1, Edward Peres 1, Danielle Pelland 2,
Susan Wautelet 2, Klodiana Neme 3, Nancy Mikulandric 3,
Kenneth Ruemenapp 2, Mary Ann Trapp 2, Sarah Szymanski 4,
Nalini Janakiraman 1. 1Hematology/Oncology and Bone
Marrow Transplantation, Henry Ford Hospital, Detroit, MI;
2 Henry Ford Hospital, Detroit, MI; 3 Pharmacy, Henry Ford
Hospital, Detroit, MI; 4 Henry Ford Hospital, Detroit, MI
The impact of early donor cell chimerism on outcomes of
reduced-intensity conditioning SCT inmyeloid disorders is ill
deﬁned. To explore the impact of measuring busulfan phar-
macokinetics (Bu PK) in conditioning regimens on early
donor chimerism, we undertook a retrospective analysis of
patients with myeloid disorders who received four days of
ﬂudarabine and busulfanwith orwithoutmeasuring Bu PK at
our center in the last 10 years.
Methods: Chimerism assay was performed using a quanti-
tative ﬂuorescence-based short tandem repeatepolymerase
chain reaction (STR-PCR) with capillary electrophoresis for
PCR product resolution.
Results: Thirty patients were identiﬁed and included in the
study. All patients received ﬂudarabine (40 mg/m2/day x 4
doses), busulfan (3.2mg/kg/dose IV x 4 doses). Of these thirty
patients, 7 had Bu PK measured. There were 21 male and 9
female patients with a median age of 62 years (range
48e72yrs). Median time to follow up was 13.3 months.
Disease risk was considered advanced in 17 patients, inter-
mediate in 3 and early in 10. All patients in the Bu PK group
had advanced disease except one had early disease.
Regarding cytogenetics, all patients in the Bu PK group had
high or intermediate risk cytogenetics. Median blast number
at time of SCT was 5%. Stem cell source included peripheral
blood in all patients.
There were no primary graft failures. Total Donor cell
Chimerism analysis in the Bu PK group showed 100% donor
at both time points (days 30,100) in all patients except in one
who relapsed at day 30 (85.7%). While in the non-PK grouponly 7 out of 23 (30%) patients had complete chimerism at
day 30 and day 100. Complete donor chimerism at day 100 in
the non-PK group was 47.8% compared to 85.7% in the PK
(p¼0.18). Ten out of 23 patients (43.5%) in the non-PK group
had decreasing donor chimerism by day 100, while in the PK
group only one patient (14%) who relapsed had decreasing
donor chimerism by day 100 with an odds ratio of 0.241 (95%
Conﬁdence Interval¼0.025-2.357; p-value¼0.22). None
developed sinusoidal obstructive syndrome.
Conclusion: In this small cohort from a single center, we
found that patients with myeloid disorders who received
ﬂudarabine busulfan for 4 days incorporating Bu PK had a
trend for higher rates of early complete donor chimerism
and less decreasing donor chimerism by day100 despite
having intermediate or high risk disease at time of SCT.
Longer follow up is needed for our patients to see if there
is effect on relapse or survival but previous studies have
showed that low or decreasing donor chimerism early after
SCT is an independent risk factor for relapse and impaired
survival. This is especially important in myeloid disorders.
Bu PK may help target better level for inducing early total
donor chimerism and donor chimerism may identify high-
risk patient cohorts who may beneﬁt from additional
therapeutic interventions.401
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The female donor/male recipient combination increases the
risks of graft-versus-host disease (GVHD) and non-relapse
mortality (NRM) after allogeneic stem cell transplantation
(allo-SCT). To explore the impact of Female matched related
donor (F-MRD) versus male matched unrelated donor
(M-MUD) on outcome of peripheral blood allo-SCT in male
recipients, we undertook a single center retrospective anal-
ysis of male adult patients transplanted at our center in the
last 10 years. We excluded patients who received donor
lymphocyte infusion post SCT.
Methods: Disease-free survival (DFS) and OSwere calculated
using the Kaplan-Meier estimate. Cumulative incidences (CI)
were used for relapse (REL) and GVHD in a competing risks
setting, NRM being a competing event for REL, and death for
GVHD.
Results: Fifty-six patients were identiﬁed and included in
this analysis. The median age at transplant was 57 years (19-
73). Diseases were AML (n¼21), ALL (n¼7), NHL (n¼9),
Hodgkin’s disease (n¼1), myeloma (n¼5), MDS (n¼11), CLL
(n¼1), and CML (n¼1). Conditioning regimens were mye-
loablative (MAC) (n¼35), reduced toxicity ablative (n¼17) or
non myelablative (n¼4). Donors were F-MRD (n¼24) or
M-MUD (n¼32). Source of stem cells was peripheral blood in
all patients. GVHD prophylaxis consisted of tacrolimus and
methotrexate in MRD and tacrolimus, methotrexate and
anti-thymocyte globulin in MUD. Of the female donors, 63%
had previous pregnancies before donation, 8% had no preg-
nancies and 29% were unknown. Mean age of female donors
was 48 while the mean age for male donors was 35.
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The median OS for patients who received M-MUD was 8.1
months while it was 14.2 months for patients who received
F-MRD (p¼0.72) Fig1. Median DFS for patients who received
M-MUD was 6 months while it was 7.2 months for patients
who received F-MRD (p¼0.94). The CI rates of aGVHD III-IV,
extensive chronic GVHD, REL and NRM at 12 months in M-
MUD vs F-MRD were 13% vs 16% (p¼0.69), 21% vs 27%
(p¼0.61), 38% vs 44% (p¼0.65), and 16% vs 14% (p¼0.79),
respectively. The CI of steroid refractory (SR) GVHD in M-
MUD vs F-MRD was 24% vs 32% (The Hazard Ratio of SR
GVHD in M-MUD vs F-MRD is 0.711 (95% conﬁdence interval
is 0.29-1.72, p¼0.45)) Fig 2. Other variables considered in
univariate analysis for SR GVHD were recipient age (p¼0.55),
disease status (p¼0.64), MAC vs other regimens (p¼0.58).
Conclusion: In this small cohort from a single center, we
found that compared to M-MUD, F-MRD had a trend for
higher rates of SR GVHD after peripheral blood allo-SCT in
adult male patients, although not statistically signiﬁcant.
There was no impact of F-MRD compared to M-MUD on OS,
DFS, REL, NRM or rates of acute or chronic GVHD. However,
the absence of statistical impact should be interpreted with
caution given the retrospective design of the study and
because we cannot exclude a possible limiting effect of a
small number of patients.Figure 1.
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Background: Primary Myeloﬁbrosis (PMF) and Post PV/ET
MF are a group of myeloproliferative neoplasms that are
characterized by marrow ﬁbrosis, cytopenias, constitutional
symptoms, and splenomegaly. Allogeneic stem cell trans-
plant (ASCT) remains the only potential curative modality.
The increased risk of morbidity and mortality warrants
careful selection of candidates. Age, performance status (PS)
and HCT-CI scores are all factors that may affect outcomes
related to ASCT. Use of JAK inhibitor therapy prior to HCT
may lead to reduction in splenomegaly, decrease in consti-
tutional symptoms, and improved PS. We report our expe-
rience here at Mayo Clinic Arizona using JAK inhibition prior
to ASCT.
Methods: We conducted a retrospective review of all pa-
tients from 2011 to current with PMF or post ET/PV-MF who
underwent treatment of ruxolitinib followed by ASCT. Pa-
tient demographic and transplant data were analyzed from a
comprehensive database. The use of such data for reporting
purpose was approved by the Mayo Clinic Arizona Institu-
tional Review Board.
Results
Patient characteristics
Eight patients underwent ruxolitinib therapy prior to
ASCT. Mean age was 61 yrs.
Disease characteristic
DIPSS risk was high risk in 6 and intermediate 2 in 2. The
JAK 2 v617 mutation was present in 7 patients. Four patients
had PMF and 4 had post PV-MF. None of the patients un-
derwent splenectomy. The median duration of ruxolitinib
was 7.8 months. Improvement in PS was seen 4 pts, stable PS
was seen 3 patients and data regarding PS was missing in 1.
Six of the 8 patients had reduction in their spleen size prior
to ASCT. The median daily dose of ruxolitinib was 25.6 mg/
day.
Transplant characteristics
One patient underwentmyeloablative conditioning (MAC),
5 reduce toxicity, and2RIC. All 8 patients hadunrelateddonors
with1patienthavingamismatchunrelateddonor.Graftversus
host disease prophylaxis was tacrolimus/methotrexate in 6
patients and tacrolimus/MMF in 2 patients. All 8 patients
received in vivo T cell depletion with rabbit ATG and had
peripheral stem cells as their graft source. Of the 8 patients, 1
hadprimarygraft failure2had relapseddiseasebeforeday100.
All 3 of these patients were conditioned with Bu/Flu RIC
regimen. None of the patients experienced tumor lysis
syndrome or cardiogenic shock.
Conclusion: In our small cohort of patients that received
ruxolitinib pre ASCT improvement in performance status and
spleen size were seen. Our data is still immature to make any
meaningful comments of outcomes, but all patients tolerated
the ruxolitinib and no major adverse outcomes were seen
related to the ruxolitinib such as cardiogenic shock or tumor
